IPO13抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08441(IPO13 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08441(IPO13 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The IPO13 antibody targets Importin 13 (IPO13), a member of the importin β family of nuclear transport receptors. IPO13 facilitates the nucleocytoplasmic shuttling of proteins and RNA by binding cargoes via specific recognition signals and interacting with the Ran GTPase cycle. Unlike many importins, IPO13 functions bidirectionally, mediating both nuclear import and export. Structurally, it contains characteristic HEAT repeats that enable cargo binding and RanGTP interaction.

IPO13 plays roles in diverse cellular processes, including transcriptional regulation, RNA processing, and developmental signaling. It transports critical cargos such as transcription factors (e.g., Pax6), RNA-binding proteins, and components of the ubiquitin-proteasome system. Studies link IPO13 to embryogenesis, stem cell differentiation, and tissue homeostasis, with knockout models showing developmental defects in mice.

In disease contexts, IPO13 dysregulation is implicated in cancer progression, neurodegenerative disorders, and viral infections. For instance, altered IPO13 expression affects the subcellular localization of oncoproteins or tumor suppressors, influencing cancer cell proliferation and metastasis. The IPO13 antibody is widely used in research to detect IPO13 expression levels, map its cellular localization via immunofluorescence or Western blotting, and investigate its cargo-specific transport mechanisms. Its applications extend to studying pathological mechanisms and potential therapeutic targets in diseases linked to nucleocytoplasmic transport defects.